Table.
Demographics of the participants in the safety set
| MVC-COV1901 group (n=3295) | Placebo group (n=549) | ||
|---|---|---|---|
| Mean age, years | 45·00 (16·27) | 44·30 (16·30) | |
| Sex | |||
| Male | 1854 (56·3%) | 318 (57·9%) | |
| Female | 1441 (43·7%) | 231 (42·1%) | |
| Race | |||
| Asian | 3294 (>99·9%) | 549 (100·0%) | |
| Non-Asian | 1 (<0·1%) | 0 | |
| Mean body-mass index, kg/m2 | 24·92 (4·07) | 24·67 (4·06) | |
| Body-mass index group, kg/m2 | |||
| <30 | 2936 (89·1%) | 499 (90·9%) | |
| ≥30 | 359 (10·9%) | 50 (9·1%) | |
| HBsAg | 197 (6·0%) | 32 (5·8%) | |
| Hepatitis C virus antibodies | 43 (1·3%) | 11 (2·0%) | |
| HIV antibodies | 58 (1·8%) | 10 (1·8%) | |
| Neutralising antibodies against wild-type SARS-CoV-2 before vaccination* | 10/930 (1·1%) | 1/154 (0·6%) | |
| Comorbidities | |||
| Any | 550 (16·7%) | 84 (15·3%) | |
| Cardiovascular disease | 90 (2·7%) | 9 (1·6%) | |
| Cerebrovascular disease | 15 (0·5%) | 2 (0·4%) | |
| Chronic obstructive pulmonary disease | 14 (0·4%) | 1 (0·2%) | |
| Liver cirrhosis | 1 (<0·1%) | 0 | |
| Malignancy | 35 (1·1%) | 7 (1·3%) | |
| Glycated haemoglobin A1c higher than normal range† | 448 (13·6%) | 69 (12·6%) | |
Data are mean (SD), n (%), or n/N (%). The safety set included all participants who had received at least one dose of study intervention.
*
Participants who had pre-vaccination neutralising antibody concentrations above lower limit of detection were considered seropositive.
†
The normal range was dependent on each local laboratory where the patients glycated haemoglobin A1c was tested.